Tagrisso

(osimertinib)
Check Coverage Restrictions
Or select your Insurance from the list below:

Dosage & Administration

Adjuvant treatment of early-stage NSCLC: 80 mg orally once daily, with or without food, until disease recurrence, or unacceptable toxicity, or for up to 3 years.

Locally advanced, unresectable (stage III) NSCLC: Following platinum-based chemoradiation therapy, 80 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.

Metastatic NSCLC: 80 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.

Locally advanced or metastatic NSCLC: 80 mg orally once daily administered in combination with pemetrexed and platinum-based chemotherapy, with or without food, until disease progression or unacceptable toxicity due to TAGRISSO.

Tagrisso Prescribing Information

Tagrisso Prior Authorization Resources

Benefits investigation

Reimbursement help (FRM)

Tagrisso PubMed™ News

    Tagrisso Patient Education

    Patient toolkit